Screener
Tarsus Pharmaceuticals, Inc. TARS Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Tarsus Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s return on equity?
- Tarsus Pharmaceuticals, Inc. (TARS) reported return on equity of -13.7% in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s return on equity changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s return on equity increased by 56.5% year-over-year, from -31.5% to -13.7%.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s return on equity?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s return on equity has grown at a 29.5% compound annual growth rate (CAGR), from -8.3% to -23.4%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude